Interview: Ahmed Zaghloul – President, Egypt Otsuka
Japanese company Otsuka envisioned Egypt as a hub for its Middle East and African operations as early as 1995. The president of the local subsidiary discusses the current activities of…
Egypt Otsuka was established in 10th of Ramadan City in 1992 aiming to supply Otsuka’s pharmaceutical products in the Egyptian market and succeeded to the business of Arab Otsuka Pharmaceutical Co., S.A.E. established in the Public Free Zone (special tax free zone for export) in Cairo in 1977. Since then, Egypt Otsuka has been engaged in manufacturing and distributing intravenous infusions and therapeutic drugs in Egypt and neighbouring countries in the Middle East as well as in Africa. Along with growing demands for intravenous infusion products in those markets, Egypt Otsuka’s production capacity has nearly reached a maximum level and its expansion has been an immediate task to meet the growing demand.
In June of 2014, acquired 80% of Ateco Pharma Egypt, an Egyptian intravenous infusion manufacturing company and has a large domestic market share. This acquisition enabled Egypt Otsuka to expand its annual production capacity of intravenous infusions by approximately 50% in volume and sufficiently meet the increasing demands in the market. Ateco Pharma Egypt was renamed as “Otsuka Ateco Pharma Egypt” following the acquisition.
Contact
ar El-Sadik St, off Dr. Abdallah El-Araby street (Tayaran), Nasr City, 11759 Cairo
Phone: 20 201 536 9561
Fax: 20 201 536 9564
Japanese company Otsuka envisioned Egypt as a hub for its Middle East and African operations as early as 1995. The president of the local subsidiary discusses the current activities of…
There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from…
GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
The memorandum of understanding includes the localization of manufacturing at EVA Pharma’s specialized and internationally accredited facility for the manufacture of immunosuppressants in the 10th of Ramadan City, Egypt, in…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
Barely four and a half years ago, Egyptian President Abdel Fattah el-Sisi secured overwhelming re-election vowing to “place public health front and centre” of a radical reform and stabilization agenda.…
Diabetes is a significant, and growing, problem in Africa, making access to insulin products a regional imperative. Some important progress is being made, including a new deal between US giant…
The leading company in the Egyptian pharma market by volume, the Egyptian International Pharmaceutical Industries Company (EIPICO) is now making a region-first move into biologicals and biosimilars manufacturing to power…
As the largest pharma market in MEA in terms of volume and second only behind Saudi in value, Egypt is an increasingly important part of pharma multinationals’ MEA operations. Here,…
Three country managers with a recent experience of bringing new products from their company’s global portfolio into Egypt – and with big plans for more launches in coming years –…
Egypt country managers tend not to stay in their roles for more than a few years, instead moving on to different pastures when new opportunities arise. However, those that do…
General manager of MEA, Khaled Elrefae, explains how Ipsen has strengthened its footprint in the region over the past two years – starting in the UAE and expanding into Saudi…
See our Cookie Privacy Policy Here